A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this trial was to verify the efficiency of a new surgical device (the LigaSure vessels sealing system) in esophagogastric decongestion and splenectomy in patients with portal hypertension.
| Condition | Intervention | Phase |
|---|---|---|
|
Liver Cirrhosis |
Device: Vessel sealing system LigaSure |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
- Operating time, from the skin incision to the final skin closure. Intraoperative blood loss, calculated by a graduated suction device and by amounts of blood involved into the sponges by the end of the operation. [ Time Frame: Within the operation ] [ Designated as safety issue: Yes ]
- Postoperative drainage volume, complications (spleen fever, bleeding and portal vein thrombosis), length of incision, postoperative pain and time to discharge. [ Time Frame: within the first 30 days after surgery ] [ Designated as safety issue: Yes ]
| Enrollment: | 60 |
| Study Start Date: | January 2006 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Vessel sealing system LigaSure (VS group)
Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
|
Device: Vessel sealing system LigaSure
Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
|
|
No Intervention: Conventional hand-tied method (CH group)
Patients in CH group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the conventional hand-tied method.
|
Detailed Description:
Bleeding from esophageal and gastric cardia varices is the major life threatening complication in patients with portal hypertension. Patients with portal hypertension have a mortality rate of 30%-50% at the first episode of esophagogastric variceal rupture. The associated 1-year mortality rate is reported to be 75%. The ideal treatment for gastric varices should effectively control bleeding and improve the liver function to optimum levels. Although endoscopic treatments have showed great promise for esophageal varices, there is still controversy regarding the treatment of gastric varices. Hepatic encephalopathy remain a dominant problems after transjugular intrahepatic portosystemic shunt placement (TIPS) and surgical shunts. A meta-analysis has shown that the incidence of hepatic encephalopathy and mortality was increased significantly either in nonselective or selective shunt operations.
Esophagogastric decongestion and splenectomy with or without esophageal transaction were the fundamental operation performed in our department for patients with portal hypertension. Patients under the azygoportal devascularization methods revealed reduction of the encephalopathy as well as diminished rebleeding rates. The crucial point of the procedure is prevention of the brisk bleeding from the dilated vessels like enlarged azygoportal collaterals. Conventional hand-tied ligatures can become dislodged and represent a foreign body, and more important, it is tedious and time-consuming. The LigaSure vessel sealing system (Valleylab, Boulder, Colorado) is a bipolar electrosurgical device, sealing vessels up to 7 mm in diameter, by denaturing collagen and elastin within vessel wall and surrounding connective tissue. This device was tested, with excellent results, in different fields of surgery (gastrointestinal, hepatopancreatobiliary, urologic, gynecologic, laparoscopic, etc), as demonstrated by several recently published studies. Shamiyeh et al confirmed the reliability of LigaSure for the closure of the veins in laparoscopic azygoportal disconnection procedure on the portal hypertension porcine model in 2005, there was no intra- or post-operative bleeding and no conversion to open surgery, and when more than 2 mm far from the thermal energy source, no collateral damage of the solid tissue such as stomach could be detected.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with liver cirrhosis accompanied by portal hypertension and secondary hypersplenism due to hepatitis, alcoholic cirrhosis or schistosomiasis, who undergoing elective azygoportal disconnection and splenectomy
Exclusion Criteria:
- Liver function as Child-Pugh C
- Hemoglobin < 9 g/dL
- Ascites
- Abnormal coagulation
Contacts and Locations| China, Shanghai | |
| Department of General Surgery, Shanghai Chang Zheng Hospital | |
| Shanghai, Shanghai, China, 200003 | |
| Study Chair: | Qiang Wang, MD | Shanghai Chang Zheng Hospital |
| Principal Investigator: | Jia Dong Gao, MD | Department of General Surgery, Shanghai Chang Zheng Hospital |
| Principal Investigator: | Wei Jun Wang, MD | Department of General Surgery, Shanghai Chang Zheng Hospital |
| Principal Investigator: | Hou Shan Yao, MD | Department of General Surgery, Shanghai Chang Zheng Hospital |
| Principal Investigator: | Zhi Qian Hu, MD | Department of General Surgery, Shanghai Chang Zheng Hospital |
More Information
No publications provided
| Responsible Party: | Qiang Wang, MD, Shanghai Chang Zheng Hospital |
| ClinicalTrials.gov Identifier: | NCT00965744 History of Changes |
| Other Study ID Numbers: | SCZH-0908-016 |
| Study First Received: | August 25, 2009 |
| Last Updated: | August 26, 2009 |
| Health Authority: | China: Ministry of Health |
Keywords provided by Shanghai Changzheng Hospital:
|
Ligasure vessel sealing system Azygoportal Disconnection Splenectomy Portal hypertension |
Additional relevant MeSH terms:
|
Hypertension Hypertension, Portal Liver Cirrhosis Fibrosis Vascular Diseases Cardiovascular Diseases Liver Diseases Digestive System Diseases Pathologic Processes Glucuronyl glucosamine glycan sulfate Anticoagulants Hematologic Agents |
Therapeutic Uses Pharmacologic Actions Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Fibrinolytic Agents Fibrin Modulating Agents Cardiovascular Agents Hypoglycemic Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 18, 2013